Previous close | 18.21 |
Open | 18.30 |
Bid | 17.53 x 800 |
Ask | 19.19 x 800 |
Day's range | 18.18 - 19.11 |
52-week range | 12.95 - 25.47 |
Volume | |
Avg. volume | 879,949 |
Market cap | 1.716B |
Beta (5Y monthly) | 0.81 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.15 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 39.20 |
HAYWARD, Calif., March 26, 2024--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 18,400 shares of the Company’s common stock at an exercise price per share of $16.47, which was the closing price on March 25, 2024, and res
Arcus Biosciences Inc (NYSE:RCUS), a company focused on the discovery, development, and commercialization of cancer immunotherapies, has reported an insider sell according to a recent SEC filing.
Arcus Biosciences Inc (NYSE:RCUS), a company focused on creating and developing cancer immunotherapies, has reported an insider sell according to a recent SEC filing.